Neo Ivy Capital Management Boosts Stock Holdings in Sotera Health (NASDAQ:SHC)

Neo Ivy Capital Management boosted its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 144.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 105,546 shares of the company's stock after acquiring an additional 62,420 shares during the quarter. Neo Ivy Capital Management's holdings in Sotera Health were worth $1,443,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SHC. Blue Trust Inc. boosted its stake in shares of Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after acquiring an additional 1,140 shares during the period. Quarry LP purchased a new stake in shares of Sotera Health in the fourth quarter worth about $28,000. Tower Research Capital LLC TRC lifted its position in shares of Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after buying an additional 1,640 shares in the last quarter. Sterling Capital Management LLC raised its position in Sotera Health by 58.5% during the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company's stock valued at $124,000 after purchasing an additional 3,331 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Sotera Health by 39.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,302 shares of the company's stock valued at $127,000 after purchasing an additional 2,627 shares during the period. Institutional investors own 91.03% of the company's stock.

Sotera Health Trading Up 0.1%

Shares of SHC stock traded up $0.02 during trading on Thursday, hitting $12.22. 138,710 shares of the stock traded hands, compared to its average volume of 1,199,060. The firm has a market capitalization of $3.47 billion, a P/E ratio of 48.82 and a beta of 1.88. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The firm's fifty day moving average price is $11.66 and its 200-day moving average price is $12.67. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $254.52 million for the quarter, compared to analyst estimates of $245.56 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. The company's revenue was up 2.6% on a year-over-year basis. As a group, research analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SHC. Piper Sandler dropped their price objective on Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Barclays dropped their target price on Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group raised Sotera Health from a "neutral" rating to a "buy" rating and increased their target price for the company from $14.00 to $17.00 in a research report on Monday, May 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $15.80.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.